Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics announced that its Board appointed Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer, succeeding David Chang, M.D., Ph.D. effective July 1, 2026. Dr. Chang’s last day as President and CEO will be June 30, 2026, after which he will remain on the Board as a non-employee director.
On the Effective Date, Dr. Roberts will also join the Board as a Class I director, serving until the 2028 annual meeting or until a successor is elected and qualified. He currently serves as Executive Vice President, Research and Development, and Chief Medical Officer, and will continue as Chief Medical Officer on an interim basis.
His new compensation includes an annualized base salary of $680,000, an annual target cash incentive of 60% of base salary, an option to purchase 476,190 shares, and a restricted stock unit award of 134,530 shares, all subject to service-based vesting. Both Dr. Roberts and Dr. Chang are entitled to severance and change in control benefits under the company’s existing Severance Plan as described in its April 30, 2026 proxy statement.
Allogene Therapeutics joint Schedule 13G/A discloses that Citadel-related entities and Kenneth Griffin report shared beneficial ownership positions in the issuer's common stock. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each report 5,795,242 shares (2.4%). Citadel Securities LLC reports 614,069 shares (0.3%). Citadel Securities Group LP and Citadel Securities GP LLC each report 1,059,878 shares (0.4%). Kenneth Griffin is reported as beneficially owning 6,855,120 shares (2.8%). The filing cites 243,777,920 Shares outstanding as of March 10, 2026 per the issuer's Form 10-K.
Allogene Therapeutics — Amendment No. 1 to a Schedule 13G/A was filed by Lynx1 Capital Management LP and Weston Nichols reporting 0 shares beneficially owned, representing 0% of the outstanding common stock as shown on the cover page. The filing states Ownership of 5 percent or less of a class and is signed by Weston Nichols on 05/15/2026.
Allogene Therapeutics amendment to a Schedule 13G/A reports beneficial ownership by Arie Belldegrun and affiliated entities of 13,466,383 shares of Common Stock, representing 5.4% of the class. The filing states 243,777,920 shares outstanding as of March 10, 2026. The cover page shows 3,866,329 shares issuable upon exercise of options within 60 days of March 31, 2026.
Allogene Therapeutics ownership update: David D. Chang and affiliated trusts report beneficial ownership of 12,297,354 shares of common stock, representing 4.9% of the class. The filing states 243,777,920 shares outstanding as of March 10, 2026.
The cover-page detail shows 6,345,007 shares exercisable within 60 days of March 31, 2026 (stock options held by Dr. Chang). Trust holdings listed include Chang 2006 Family Trust 1,201,108 shares, JEC 2019 Trust 856,044 shares, and RTC 2019 Trust 856,044 shares.
Allogene Therapeutics, Inc. reported a net loss of $42.6 million for the quarter ended March 31, 2026, improving from $59.7 million a year earlier as total operating expenses fell to $46.1 million from $65.2 million.
Cash, cash equivalents and investments totaled $266.9 million at quarter‑end, before an additional $187.9 million in net proceeds from an April 2026 equity offering of 100.2 million shares at $2.00 per share. The company now expects its cash resources to fund operations into the first quarter of 2029.
Allogene continues to focus on three core programs: the pivotal ALPHA3 trial of cema‑cel in first‑line large B‑cell lymphoma, the TRAVERSE study of ALLO‑316 in renal cell carcinoma, and the RESOLUTION basket trial of ALLO‑329 in autoimmune diseases, all supported by its Dagger® platform and multiple external collaborations.
Allogene Therapeutics reported first quarter 2026 results and a major portfolio change. The company terminated its exclusive license with Overland covering four CAR T targets in parts of Asia, with no termination payments, and restructured its Overland ownership and governance; Allogene now expects to hold about 3% of Overland’s equity.
Interim data from the pivotal Phase 2 ALPHA3 trial showed 58.3% of patients on cemacabtagene ansegedleucel achieved minimal residual disease clearance versus 16.7% on observation, with a 97.7% median ctDNA reduction and no CRS, ICANS, GvHD, treatment-related serious events or hospitalizations. In autoimmune disease, nine patients have been treated in the Phase 1 RESOLUTION trial of ALLO-329 with early signs of activity and favorable tolerability.
Research and development expense was $32.0 million and general and administrative expense was $14.1 million, leading to a net loss of $42.6 million, or $0.18 per share. Allogene ended the quarter with $266.9 million in cash, cash equivalents and investments, and an April 2026 public offering added $200.4 million in gross proceeds, extending projected cash runway into the first quarter of 2029. The company now guides 2026 operating cash expense to about $165 million and GAAP operating expenses to about $225 million.
Allogene Therapeutics is asking stockholders to vote at its fully virtual 2026 annual meeting on June 18, 2026. The agenda includes electing three Class II directors, advisory votes on executive pay and pay vote frequency, and ratifying Ernst & Young LLP as auditor.
The company is also requesting approval of an Authorized Shares Amendment to double authorized common stock from 400,000,000 to 800,000,000 shares. The record date is April 20, 2026, when 345,024,351 shares of common stock were outstanding and entitled to vote.
Frazier-affiliated investors report shared ownership stakes in Allogene Therapeutics common stock. Frazier Life Sciences Public Fund, L.P. holds 16,205,306 shares (4.7%). Related Frazier funds hold additional positions: 306,906 shares (0.1%), 722,956 shares (0.2%), and 1,561,500 shares (0.5%) in separate partnerships. The percent calculations reference 243,777,920 shares outstanding as of March 10, 2026 and incorporate 100,200,000 shares sold by the issuer on April 16, 2026.